Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:13:37.047Z.
Calculation as of: 2026-10-06T19:13:37.047Z.
Quote observation: 2026-10-06T19:10:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 79812cd6dc1246c3578cfde2233ee829467ffef9b0062efd9074e0cc555abd58
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$692.67M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$692.83M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$663.91M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | $679.58M | N/A | N/A | N/A | N/A |
| Verastem, Inc. (VSTM)vs › | $687.02M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $668.94M | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $690.71M | N/A | N/A | N/A | N/A |
| Wave Life Sciences Ltd. (WVE)vs › | $690.75M | N/A | N/A | N/A | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $692.67M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $692.83M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $664.49M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $663.91M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $661.02M | 16.29 | 12.94 | 32.63 | 32.63 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
